

Claims

1. Use of a metabotropic glutamate receptor 5 antagonist, or a pharmaceutically acceptable salt or an optical isomer thereof, for the manufacture of a medicament  
5 for the treatment of a functional gastrointestinal disorder.
2. Use according to claim 1, wherein the functional gastrointestinal disorder is functional dyspepsia.
- 10 3. Use according to any one of the preceding claims, wherein the metabotropic glutamate receptor 5 antagonist is 2-methyl-6-(phenylethynyl)-pyridine.
4. Use according to claim 4, wherein the metabotropic glutamate receptor 5 antagonist is the hydrochloride salt of 2-methyl-6-(phenylethynyl)-pyridine.  
15
5. A method for the treatment of a functional gastrointestinal disorder whereby a pharmaceutically and pharmacologically effective amount of a metabotropic glutamate receptor 5 antagonist, or a pharmaceutically acceptable salt or an optical isomer thereof, is administered to a subject in need of such treatment.  
20
6. The method according to claim 5, wherein the functional gastrointestinal disorder is functional dyspepsia.
7. A method according to any one of claims 5 or 6, wherein the metabotropic  
25 glutamate receptor 5 antagonist is 2-methyl-6-(phenylethynyl)-pyridine.
8. A method according to claim 7, wherein the metabotropic glutamate receptor 5 antagonist is the hydrochloride salt of 2-methyl-6-(phenylethynyl)-pyridine.